Puma Biotechnology
PBYI
99 hedge funds and large institutions have $101M invested in Puma Biotechnology in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 20 closing their positions.
396% more call options, than puts
Call options by funds: $417K | Put options by funds: $84K
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
27% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 26
6% more funds holding
Funds holding: 93 → 99 (+6)
2.52% more ownership
Funds ownership: 61.7% → 64.22% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
36% less capital invested
Capital invested by funds: $158M → $101M (-$56.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.58M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.18M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$1.61M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.5M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$8.74M |
| 2 |
Jane Street
New York
|
-$1.82M |
| 3 |
Morgan Stanley
New York
|
-$1.29M |
| 4 |
Goldman Sachs
New York
|
-$1.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$905K |
PBYI Hedge Fund Activity: Q2 2024 in Review
99 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2024, worth a combined $101M — down 36% from $158M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PBYI positions and 20 closed out — a net gain of 6 holders — while 33 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $8.58M. The largest seller was Camber Capital Management, exiting entirely with an estimated $8.74M sold.
- 99 institutional investors held Puma Biotechnology (PBYI) as of Q2 2024, up from 93 in Q1 2024.
- Funds reported $101M of Puma Biotechnology stock for Q2 2024, down 36% quarter-over-quarter.
- 26 funds opened new Puma Biotechnology positions in Q2 2024 and 20 closed out, a net change of +6 holders.
- The largest Puma Biotechnology buyer in Q2 2024 was BlackRock, an estimated $8.58M added.
- The largest Puma Biotechnology seller in Q2 2024 was Camber Capital Management, an estimated $8.74M sold.
Based on aggregated 13F filings for Q2 2024.